Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 157

1.

Possible Contribution of Drug Approval Summaries Published by Drug Regulatory Authorities on Scientific Discussion and Drug Development.

Tanese K, Yamori T.

Clin Pharmacol Drug Dev. 2019 Oct 14. doi: 10.1002/cpdd.744. [Epub ahead of print] No abstract available.

PMID:
31608600
2.

Discovery of Inhibitors of Membrane Traffic from a Panel of Clinically Effective Anticancer Drugs.

Kamata H, Sadahiro S, Yamori T.

Biol Pharm Bull. 2019 May 1;42(5):814-818. doi: 10.1248/bpb.b18-01026. Epub 2019 Feb 21.

3.

Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines.

Namatame N, Tamaki N, Yoshizawa Y, Okamura M, Nishimura Y, Yamazaki K, Tanaka M, Nakamura T, Semba K, Yamori T, Yaguchi SI, Dan S.

Oncotarget. 2018 Oct 12;9(80):35141-35161. doi: 10.18632/oncotarget.26216. eCollection 2018 Oct 12.

4.

Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells.

Fujiwara C, Muramatsu Y, Nishii M, Tokunaka K, Tahara H, Ueno M, Yamori T, Sugimoto Y, Seimiya H.

Sci Rep. 2018 Oct 4;8(1):14827. doi: 10.1038/s41598-018-33139-x.

5.

TUFT1 interacts with RABGAP1 and regulates mTORC1 signaling.

Kawasaki N, Isogaya K, Dan S, Yamori T, Takano H, Yao R, Morishita Y, Taguchi L, Morikawa M, Heldin CH, Noda T, Ehata S, Miyazono K, Koinuma D.

Cell Discov. 2018 Jan 9;4:1. doi: 10.1038/s41421-017-0001-2. eCollection 2018.

6.

Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.

Ohashi Y, Okamura M, Katayama R, Fang S, Tsutsui S, Akatsuka A, Shan M, Choi HW, Fujita N, Yoshimatsu K, Shiina I, Yamori T, Dan S.

Oncotarget. 2017 Dec 6;9(2):1641-1655. doi: 10.18632/oncotarget.22895. eCollection 2018 Jan 5.

7.

Family-wide Analysis of the Inhibition of Arf Guanine Nucleotide Exchange Factors with Small Molecules: Evidence of Unique Inhibitory Profiles.

Benabdi S, Peurois F, Nawrotek A, Chikireddy J, Cañeque T, Yamori T, Shiina I, Ohashi Y, Dan S, Rodriguez R, Cherfils J, Zeghouf M.

Biochemistry. 2017 Sep 26;56(38):5125-5133. doi: 10.1021/acs.biochem.7b00706. Epub 2017 Sep 13.

PMID:
28858527
8.

Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole.

Nakamura T, Okabe S, Yoshida H, Iida K, Ma Y, Sasaki S, Yamori T, Shin-Ya K, Nakano I, Nagasawa K, Seimiya H.

Sci Rep. 2017 Jun 15;7(1):3605. doi: 10.1038/s41598-017-03785-8.

9.

A novel thiophene-3-carboxamide analog of annonaceous acetogenin exhibits antitumor activity via inhibition of mitochondrial complex I.

Akatsuka A, Kojima N, Okamura M, Dan S, Yamori T.

Pharmacol Res Perspect. 2016 Jul 12;4(4):e00246. doi: 10.1002/prp2.246. eCollection 2016 Aug.

10.

Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors.

Narita K, Matsuhara K, Itoh J, Akiyama Y, Dan S, Yamori T, Ito A, Yoshida M, Katoh T.

Eur J Med Chem. 2016 Oct 4;121:592-609. doi: 10.1016/j.ejmech.2016.05.031. Epub 2016 May 18.

PMID:
27318982
11.

M-COPA, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin.

Hattori T, Watanabe-Takahashi M, Shiina I, Ohashi Y, Dan S, Nishikawa K, Yamori T, Naito M.

Genes Cells. 2016 Aug;21(8):901-6. doi: 10.1111/gtc.12386. Epub 2016 Jun 15.

12.

M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.

Ohashi Y, Okamura M, Hirosawa A, Tamaki N, Akatsuka A, Wu KM, Choi HW, Yoshimatsu K, Shiina I, Yamori T, Dan S.

Cancer Res. 2016 Jul 1;76(13):3895-903. doi: 10.1158/0008-5472.CAN-15-2220. Epub 2016 Apr 12.

13.

Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.

Takemoto Y, Ito A, Niwa H, Okamura M, Fujiwara T, Hirano T, Handa N, Umehara T, Sonoda T, Ogawa K, Tariq M, Nishino N, Dan S, Kagechika H, Yamori T, Yokoyama S, Yoshida M.

J Med Chem. 2016 Apr 28;59(8):3650-60. doi: 10.1021/acs.jmedchem.5b01732. Epub 2016 Apr 18.

PMID:
27088648
14.

Pyrrocidine A, a metabolite of endophytic fungi, has a potent apoptosis-inducing activity against HL60 cells through caspase activation via the Michael addition.

Uesugi S, Fujisawa N, Yoshida J, Watanabe M, Dan S, Yamori T, Shiono Y, Kimura K.

J Antibiot (Tokyo). 2016 Mar;69(3):133-40. doi: 10.1038/ja.2015.103. Epub 2015 Oct 28.

PMID:
26506860
15.

Identification of a molecular target of kurahyne, an apoptosis-inducing lipopeptide from marine cyanobacterial assemblages.

Iwasaki A, Ohno O, Katsuyama S, Morita M, Sasazawa Y, Dan S, Simizu S, Yamori T, Suenaga K.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5295-8. doi: 10.1016/j.bmcl.2015.09.044. Epub 2015 Sep 21.

PMID:
26428873
16.

Ridaifen G, tamoxifen analog, is a potent anticancer drug working through a combinatorial association with multiple cellular factors.

Ikeda K, Kamisuki S, Uetake S, Mizusawa A, Ota N, Sasaki T, Tsukuda S, Kusayanagi T, Takakusagi Y, Morohashi K, Yamori T, Dan S, Shiina I, Sugawara F.

Bioorg Med Chem. 2015 Sep 15;23(18):6118-24. doi: 10.1016/j.bmc.2015.08.001. Epub 2015 Aug 5.

PMID:
26314924
17.

Biselyngbyasides, cytotoxic marine macrolides, are novel and potent inhibitors of the Ca(2+) pumps with a unique mode of binding.

Morita M, Ogawa H, Ohno O, Yamori T, Suenaga K, Toyoshima C.

FEBS Lett. 2015 Jun 4;589(13):1406-11. doi: 10.1016/j.febslet.2015.04.056. Epub 2015 May 6.

18.

Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.

Mashima T, Ushijima M, Matsuura M, Tsukahara S, Kunimasa K, Furuno A, Saito S, Kitamura M, Soma-Nagae T, Seimiya H, Dan S, Yamori T, Tomida A.

Cancer Sci. 2015 Jul;106(7):909-20. doi: 10.1111/cas.12682. Epub 2015 May 25.

19.

Stromal cells positively and negatively modulate the growth of cancer cells: stimulation via the PGE2-TNFα-IL-6 pathway and inhibition via secreted GAPDH-E-cadherin interaction.

Kawada M, Inoue H, Ohba S, Yoshida J, Masuda T, Yamasaki M, Usami I, Sakamoto S, Abe H, Watanabe T, Yamori T, Shibasaki M, Nomoto A.

PLoS One. 2015 Mar 18;10(3):e0119415. doi: 10.1371/journal.pone.0119415. eCollection 2015.

20.

Abdominal Infection Suppresses the Number and Activity of Intrahepatic Natural Killer Cells and Promotes Tumor Growth in a Murine Liver Metastasis Model.

Matsumoto Y, Tsujimoto H, Ono S, Shinomiya N, Miyazaki H, Hiraki S, Takahata R, Yoshida K, Saitoh D, Yamori T, Yamamoto J, Hase K.

Ann Surg Oncol. 2016 Feb;23 Suppl 2:S257-65. doi: 10.1245/s10434-015-4466-7. Epub 2015 Mar 10.

PMID:
25752891

Supplemental Content

Loading ...
Support Center